Page 30 - Test PDF v5

« Back to Contents ENDOMETRIAL CANCER

LiFE re

Literature for ENYGO

Surgical treatment of recurrent endometrial cancer

Editor Arun Kalpdev

Descriptive summary Turan et al. analysed the effects of salvage cytoreductive surgery
among 34 patients with REC. An optimal result with no visible
Due to a paucity of well-designed trials, there is still no final residual tumour was achieved in 68.2 % of the patients treated via
verdict for the management of recurrent endometrial cancer (REC). the laparotomy route. None of the factors was associated with the
Recently, European experts on behalf of the European Society for achievement of optimal cytoreduction [4].
Medical Oncology (ESMO), the European Society for Radiotherapy
& Oncology (ESTRO) and the European Society of Gynaecological The following studies reported on different surgical techniques
Oncology (ESGO), have developed recommendations and consensus for the treatment of REC. Gallotta et al. presented a video of the
on endometrial cancer diagnosis, treatment and follow-up [1]. The laparoscopic management of REC, mainly focusing on small bowel
authors emphasise that recurrent disease should only be considered resection with intracorporeal anastomosis and partial colpectomy
for surgery if cytoreduction with no macroscopic residual disease is [5]. Menderes et al. showed a surgical video in which an isolated
achievable. The performance of lymphadenectomy in cytoreduction hemidiaphragmatic tumour nodule was resected laparoscopically in
is not being favoured, due to lack of effect on overall survival (OS) a patient with isolated REC [6]. Kato et al. presented the cytoreduc-
and progression-free survival (PFS). The retrospective analysis of tion of metastatic para-aortic lymph nodes with involvement of the
Papadia et al. supports these recommendations, showing better inferior vena cava, requiring its partial resection and repair [7].
overall survival (OS) and progression-free survival (PFS) after optimal
cytoreduction [2]. The estimated 5-year overall survival (OS) was
60 % and 30 % in optimally and suboptimally cytoreduced patients,
respectively.

Hardarson et al. retrospectively evaluated the efficacy of radiother-
apy and surgical treatment in a non-irradiated group of 33 patients
with REC limited to the vaginal vault. Authors indicated that a surgi-
cal approach is an appropriate treatment for locally REC [3].

Relevant articles retrieved Nov 2015 - Feb 2016 (cont.)

No Title Authors Journal Link to abstract
Colombo N et al. Radiother Oncol.
1 ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagno- Papadia A et al. Ann Surg Oncol. http://www.ncbi.nlm.nih.gov/
sis, treatment and follow-up. Hardarson HA et al. Gynecol Oncol Rep. pubmed/26683800
Turan et al. Int J Gynecol Cancer.
2 Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm J Minim Invasive Gynecol. http://www.ncbi.nlm.nih.gov/
Shift. J Minim Invasive Gynecol. pubmed/25777095

3 Vaginal vault recurrences of endometrial cancer in non-irradiated patients - http://www.ncbi.nlm.nih.gov/
Radiotherapy or surgery. pubmed/26076091

4 Salvage Cytoreductive Surgery for Recurrent Endometrial Cancer. http://www.ncbi.nlm.nih.gov/
pubmed/26397154
5 Laparoscopic Management of a Small Bowel Recurrence of Endometrial Gallotta et al.
Cancer. http://www.ncbi.nlm.nih.gov/
pubmed/26408229
6 Laparoscopic Resection of the Diaphragmatic Tumor Nodule for Management Menderes G et al.
of Recurrent Endometrial Cancer. http://www.ncbi.nlm.nih.gov/
pubmed/26776674

Continued on the next page  Page 30

International Journal of Gynecological Cancer, Volume 26, Supplement #1